CM
AZN icon

Corvex Management’s AstraZeneca AZN Stock Holding History

Corvex Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-1,238,000
Closed -$90.6M – 49
2014
Q2 		$92M Buy
+1,238,000
New +$89.5M 1.09% 23

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
MAA
Managed Account Advisors Jersey City, New Jersey $121B AUM 7.32% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Corvex Management's AZN Position: Q3 2014 in Review

Corvex Management sold out of AstraZeneca (AZN) in Q3 2014, closing a stake of 1,238,000 shares — an estimated $90.6M sold.

Corvex Management first reported a position in AZN in Q2 2014 and held it in 1 quarter. The position peaked at $92M in Q2 2014. 401 funds tracked by Wall St. Rank hold AZN as of Q3 2014.

  • Corvex Management reported no remaining AstraZeneca position as of Q3 2014 after selling out during the quarter.
  • Corvex Management sold 1,238,000 AstraZeneca shares in Q3 2014, an estimated $90.6M.
  • Corvex Management first reported a position in AstraZeneca in Q2 2014 and held it in 1 quarter.
  • Corvex Management's AstraZeneca position peaked at $92M in Q2 2014.
  • 401 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2014.

Based on Corvex Management's 13F filing for Q3 2014, filed 14 Nov 2014.